Tumor necrosis factor-a (TNF-a) is a well-studied proinflammatory cytokine that contributes to the pathogenesis of immune and infectious diseases. TNF-a effects are mediated by signaling through TNF-a receptors, which are present ubiquitously. 1 Limiting the actions of TNF-a, either by blocking the receptor or inhibiting circulating (free) TNF-a, is a useful treatment strategy in autoimmune disorders with prominent inflammation, such as inflammatory bowel disease and rheumatoid arthritis (RA). However, when treatment with agents that inhibit TNF-a function was applied to multiple sclerosis (MS), an unanticipated worsening was observed. The clinical trial of lenercept (a recombinant TNF-a receptor-immunoglobulin 1g fusion protein that protected against experimental autoimmune encephalitis) for the treatment of relapsingremitting multiple sclerosis was stopped prematurely when the treatment arm was noted to have earlier and more frequent exacerbations.
2 TNF-a antagonists are therefore contraindicated in patients with MS. In patients with no history of demyelinating disease, TNF-a antagonism has led to unmasking of demyelinating events with a clinical pattern typical of that seen in MS. 3 All CNS cases of demyelinating disease to date have been based on clinical, laboratory, and radiographic findings. Herein we present a unique case of histologically confirmed demyelination following treatment with TNFa inhibitors.
Case report. A 57-year-old man with chronic obstructive pulmonary disease and RA managed with infliximab (a monoclonal antibody against TNF-a), methotrexate, and low-dose prednisone presented with 5 days of progressive encephalopathy, right facial weakness, ataxia, and rash.
The patient had started infliximab 4 months prior to presentation and had persistent hoarseness after pneumonia, which was treated empirically with clarithromycin. He then developed a nonpruritic rash that spread centrifugally and concurrently developed subacute, progressive right lower motor neuron facial nerve weakness, ataxia, and encephalopathy.
On admission, the patient was treated with broadspectrum antimicrobials including bacterial, fungal, viral, and rickettsial coverage. Chest CT demonstrated lower lobe consolidations. Brain MRI demonstrated multiple lesions suggesting demyelination in the pons, middle cerebellar peduncle, right striatum, and left parietal lobe (figure, A).
The patient had leukopenia and mildly elevated liver transaminases. CSF studies were all normal other than a mildly elevated immunoglobulin G index at 0.74; no oligoclonal bands were detected. Extensive serum and CSF infectious studies were negative, including JC virus, enterovirus, EpsteinBarr virus, cytomegalovirus, varicella-zoster virus, herpes simplex virus, HIV, fungal, mycobacterial, and rickettsial testing. A biopsy of his rash was obtained and the histologic differential diagnosis included an autoimmune connective tissue disease, erythema multiforme, viral or rickettsial illness, and methotrexate-induced toxicity.
The patient's neurologic examination and the brain MRI lesions progressed over several days, and he was treated with high-dose steroids for a presumed autoimmune demyelinating syndrome with initial improvement. However, he later worsened despite plasma exchange and broad-spectrum antimicrobials.
Blood cultures grew pan-resistant Klebsiella pneumoniae and despite optimal antimicrobial treatment, the patient developed septic shock with multiorgan dysfunction and died. Brain histopathology demonstrated an acute demyelinating process.
Discussion. The case presented herein provides pathologic proof of a demyelinating process following TNF-a antagonism. The demyelinated areas correlated with those identified by MRI. Gross sections from these areas showed large regions of parenchymal pallor. Histochemical and immunostaining of these regions showed dense infiltrates of macrophages (CD681) and reactive glial fibrillary acid proteinpositive astrocytes. Perivascular lymphocytic infiltration was also observed, as were small foci of necrosis, a feature that has been reported with Marburg-type MS. 4 The lesions primarily involved white matter; however, the process focally extended to involve the gray matter as well. The histologic findings were specific for a demyelinating process (figure, B and C). Zones of demyelination were not vasculocentric, and the clinical and MRI picture was unlike that seen in acute disseminated encephalomyelitis.
Previous reports of demyelinating disease associated with TNF-a antagonism have included a variety of clinical manifestations of demyelination, 5 as have a number of dermatologic adverse reactions. 6 Most neurologic manifestations attenuate with cessation of TNF-a antagonism, but one study found that roughly 25% of patients developed MS despite discontinuation. 7 A French national survey identified 22 patients with a central demyelination syndrome and 11 with peripheral manifestations, 2 of whom had peripheral nerve biopsies demonstrating demyelination. 7 CSF findings in previously reported cases have been variable, ranging from normal to pleocytosis with oligoclonal bands.
Several mechanisms relating to TNF-a and demyelinating events have been proposed. 3 For example, prolonged exposure to TNF-a antagonism may enhance the antigen-specific T-cell response or alter the cytokine profile, both of which possibly favor demyelination. TNF-a antagonism has not been shown to induce demyelination in experimental autoimmune encephalitis 2 and the mechanistic understanding of the relationship between TNF-a antagonism and demyelination remains unclear. 
